Schonfeld Strategic Advisors LLC Has $658,000 Position in Masimo Co. (NASDAQ:MASI)

Schonfeld Strategic Advisors LLC lowered its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 54.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,980 shares of the medical equipment provider's stock after selling 4,811 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Masimo were worth $658,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Jones Financial Companies Lllp purchased a new position in shares of Masimo during the 4th quarter worth $27,000. UMB Bank n.a. lifted its position in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after buying an additional 123 shares during the period. Blue Trust Inc. boosted its stake in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares during the last quarter. Trust Co. of Vermont purchased a new stake in Masimo in the 4th quarter valued at about $33,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 64 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Down 1.2%

Shares of NASDAQ:MASI traded down $2.00 during mid-day trading on Tuesday, hitting $161.56. 536,884 shares of the company traded hands, compared to its average volume of 659,352. The firm has a market cap of $8.76 billion, a P/E ratio of 111.42 and a beta of 1.23. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The firm's 50 day simple moving average is $161.21 and its 200 day simple moving average is $167.10. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. During the same period in the prior year, the company posted $0.77 EPS. The business's revenue for the quarter was down 24.5% compared to the same quarter last year. On average, equities analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Piper Sandler reaffirmed an "overweight" rating and issued a $200.00 target price (down from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Raymond James lowered their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $191.60.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This represents a 11.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. This trade represents a 55.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.